**99 Hyperbilirubinemia: Unconjugated**

**Selected References**

American Academy of Pediatrics. Clinical practice guideline: management of hyperbilirubinemia in the newborn infant 35 weeks or more weeks of gestation. *Pediatrics.* 2004;114:297-316.

Arnold C, Pedroza C, Tyson JE. Phototherapy in ELBW newborns: does it work? Is it safe? The evidence from randomized clinical trials. *Semin Perinatol.* 2014;38:452-464

Bhutani VK, Poland R, Meloy LD, et al. Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia. *J Perinatol*. 2016;36:533-539.

Bhutani VK, Wong R. Bilirubin-induced neurologic dysfunction (BIND). *Semin Fetal Neonatal Med.* 2015;20:1.

Bhutani VK, Wong RJ, Stevenson DK. Hyperbilirubinemia in preterm neonates. *Clin Perinatol*. 2016;43:215-232.

Christensen RD, Lambert DK, Henry E, et al. End-tidal carbon monoxide as an indicator of the hemolytic rate. *Blood Cells Mol Dis*. 2015;54:292-296

Kaplan M, Hammerman C, Bhutani VK. The preterm infant: a high-risk situation for neonatal hyperbilirubinemia due to glucose-6-phosphate dehydrogenase deficiency. *Clin Perinatol.* 2016;43:325-340.

Louis D, More K, Oberoi S, Shah PS. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis. *Arch Dis Child Fetal Neonatal Ed.* 2014;99:F325-F331.

Mahajan V, Jain SK. Hereditary spherocytosis. *NeoReviews* 2016;17:e697-e704.

Maisels MJ, Clune S, Coleman K, et al. The natural history of jaundice in predominantly breastfed infants. *Pediatrics* 2014;134:e340-e345.

Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. *J Perinatol*. 2012;32:660-664.

Norman M, Åberg K, Holmsten K, et al. Predicting nonhemolytic neonatal hyperbilirubinemia.

*Pediatrics*. 2015;136:1087-1094.

Quist FK, Bapat R, Kuch-Kunich HK, et al. Clinical utility of transcutaneous bilirubinometer (TcB) in very low birth weight (VLBW) infants. *J Perinat Med*. 2016;44:933-939.

Sachdeva M, Murki S, Oleti TP, Kandraju H. Intermittent versus continuous phototherapy for the treatment of neonatal non-hemolytic moderate hyperbilirubinemia in infants more than 34 weeks of gestational age: a randomized controlled trial. *Eur J Pediatr*. 2015;174:177-1781.

Shapiro S, Le Pichon JB, Riordan SM, Watchkoe J. The neurological sequelae of neonatal hyperbilirubinemia: definitions, diagnosis and treatment of the kernicterus spectrum disorders (KSDs). [*Curr Pediatr Rev*.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Watchkoe%20J%5BAuthor%5D&cauthor=true&cauthor_uid=28814249) 2017;13(3):199-209.

Skierka JM, Kotzer KE, Lagerstedt SA, et al. UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia. *J Pediatr* 2013;162:1146-1152.

Taylor JA, Burgos AE, Flaherman V, et al. Discrepancies between transcutaneous and serum bilirubin measurements. *Pediatrics*. 2015;135:224-231.

Tidmarsh GF, Wong RJ, Stevenson DK, et al. End-tidal carbon monoxide and hemolysis. *J Perinatol.* 2014;34:577-581.

Wickremasinghe AC, Kuzniewicz MW, Grimes BA, et al. Neonatal phototherapy and infantile cancer. *Pediatrics*. 2016;137:6.